Research programme: rheumatoid arthritis therapy - Sanofi Genzyme

Drug Profile

Research programme: rheumatoid arthritis therapy - Sanofi Genzyme

Alternative Names: RB-2002; RB-2003

Latest Information Update: 15 Dec 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genzyme Corporation
  • Class
  • Mechanism of Action Macrophage inhibitors; Nitric oxide synthase inhibitors; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Rheumatoid arthritis

Most Recent Events

  • 04 May 2006 No development reported - Preclinical for Rheumatoid arthritis in USA (unspecified route)
  • 30 Mar 2004 SangStat's operations have been absorbed into Genzyme Corporation's Cambridge site
  • 14 Nov 2003 Preclinical trials in Rheumatoid arthritis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top